Company intelligence / Profile preview
Curevo Vaccine
Bothell, Washington, United Statescurevovaccine.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Curevo’s lead vaccine candidate for shingles has demonstrated excellent immunogenicity and improved tolerability in clinical studies. The company completed a successful Phase I trial showing robust antibody responses with good safety, followed by positive results in later-stage trials. Their approach focuses on non-mRNA adjuvanted subunit vaccines to address issues of tolerability and accessibility seen with current market leaders like Shingrix®.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Adjuvanted subunit vaccines (non-mRNA)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
GC Pharma/GC Biopharma/MOGAM Institute for Biomedical Research – research collaboration partner and founding investorIDRI – initial research collaboration partner
Beyond the preview
Go deeper on Curevo Vaccine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Curevo Vaccine.